Show notes
Manufacturers can expect to face unforeseen hurdles when they begin to mass-produce a brand new pharmaceutical product, and in a pandemic, there are bound to be supply chain problems as well. But in late 2020, Pfizer was delivering fewer doses than the government expected and then-federal officials told NPR they did not know why.
See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.
NPR Privacy Policy
See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.
NPR Privacy Policy



